Shares of Sorrento Therapeutics, Inc. (SRNE) have traded between $1.39 – 6.5. The next earnings date is set for Mar 20, 2020. Let’s see how its prospects are shaping up.

What does Sorrento Therapeutics, Inc.(SRNE) do?

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.

SRNE Insider Trading Insight

On 2018-09-12, Abg Management Ltd 10% sold 297,568 shares of SRNE. That represents a value of $6,791,335. Not to be outdone, on 2018-02-28, Ng George K P – Purchase bought90,000 shares of SRNE. These insiders are clearly in the know because they work closely with the company.

The AAN Consensus Price Target

The mean recommendation of Aaron’s, Inc. from top Wall Street analysts is a Strong Buy. That is based on 6 analysts who work on the Street. Based on 6 analysts offering 12 month price targets for Aaron’s in the last 3 months. The average price target is $84.33 with a high forecast of $90.00 and a low forecast of $80.00. The average price target represents a 41.35% increase from the last price of $59.66. Last week, several articles were published in financial papers about AAN and 37% Bearish while 63% Bullish.

AAN Intraday Trading

AAN is due to report earnings on Feb 13, 2020. In the last year the price has ranged from 45.71 – 78.66. Recently, Doman Curtis Linn sold 10,000 shares of AAN. He is a $126,660 shareholder in AAN.

Looking for stocks similar to SRNE and AAN?

Here are some stocks to consider:
ELOX
RARX
RCII
CONN